Search Results
You are looking at 1 - 4 of 4 items for
- Author: M E Caplin x
- Refine by access: All content x
Search for other papers by R Srirajaskanthan in
Google Scholar
PubMed
Search for other papers by G Dancey in
Google Scholar
PubMed
Search for other papers by A Hackshaw in
Google Scholar
PubMed
Search for other papers by T Luong in
Google Scholar
PubMed
Search for other papers by M E Caplin in
Google Scholar
PubMed
Search for other papers by T Meyer in
Google Scholar
PubMed
Angiogenesis is an essential process in the development and growth of tumours. There are a large number of angiogenic mediators including the angiopoietin (Ang) family and vascular endothelial growth factor, which play an important role in both physiological and pathological angiogenesis. This study examines serum levels of Ang-1 and Ang-2 in patients with neuroendocrine tumour (NET) compared healthy controls. ELISA for Ang-1 and Ang-2 was performed in 47 patients with histologically proven NETs and 44 healthy controls. Immunohistochemical staining for Ang-2 was performed in patients to demonstrate cellular location of Ang-2. Serum Ang-2 levels were significantly elevated in patients compared controls (median 4756 vs 2495 pg/ml, P<0.001), while there was no significant difference in Ang-1 levels. The ratio of Ang-2:Ang-1 was significantly elevated in patients compared controls (0.13 vs 0.066, P<0.001). Serum Ang-2 levels were significantly elevated in patients with distant metastases compared with those without metastasis (median 5080 vs 3360 pg/ml, P=0.01). There was also a significant increase between Ang-2 levels and volume of liver metastases (P=0.014). Time to disease progression was worse in patients with serum Ang-2 levels >4756 pg/ml (P=0.04). Serum Ang-2 but not Ang-1 is elevated in NET patients. Ang-2 may be a useful serum marker for monitoring and assessment of prognosis in patients with NETs.
Search for other papers by E Baudin in
Google Scholar
PubMed
Search for other papers by J Capdevila in
Google Scholar
PubMed
Search for other papers by D Hörsch in
Google Scholar
PubMed
Search for other papers by S Singh in
Google Scholar
PubMed
Search for other papers by M E Caplin in
Google Scholar
PubMed
Search for other papers by E M Wolin in
Google Scholar
PubMed
Search for other papers by W Buikhuisen in
Google Scholar
PubMed
Search for other papers by M Raderer in
Google Scholar
PubMed
Search for other papers by E Dansin in
Google Scholar
PubMed
Search for other papers by C Grohe in
Google Scholar
PubMed
Search for other papers by D Ferone in
Google Scholar
PubMed
Search for other papers by A Houchard in
Google Scholar
PubMed
Search for other papers by X-M Truong-Thanh in
Google Scholar
PubMed
Search for other papers by D Reidy-Lagunes in
Google Scholar
PubMed
Search for other papers by the SPINET Study Group in
Google Scholar
PubMed
Prospective data are lacking on early somatostatin analog (SSA) therapy in bronchopulmonary neuroendocrine tumors (BP-NETs; typical carcinoids and atypical carcinoids (TCs and ACs)). SPINET (EudraCT: 2015-004992-62; NCT02683941) was a phase III, double-blind study of lanreotide autogel/depot (LAN; 120 mg every 28 days) plus best supportive care (BSC) vs placebo plus BSC, with an optional open-label treatment phase (LAN plus BSC). Patients had metastatic/unresectable, somatostatin receptor (SSTR)-positive TCs or ACs. Recruitment was stopped early owing to slow accrual; eligible patients from the double-blind phase transitioned to open-label LAN. The adapted primary endpoint was progression-free survival (PFS) during either phase for patients receiving LAN. Seventy-seven patients were randomized (LAN, n = 51 (TCs, n = 29; ACs, n = 22); placebo, n = 26 (TCs, n = 16; ACs, n = 10)). Median (95% CI) PFS during double-blind and open-label phases in patients receiving LAN was 16.6 (11.3; 21.9) months overall (primary endpoint), 21.9 (12.8, not calculable (NC)) months in TCs, and 13.8 (5.4; 16.6) months in ACs. During double-blind treatment, median (95% CI) PFS was 16.6 (11.3; 21.9) months for LAN vs 13.6 (8.3; NC) months for placebo (not significant); corresponding values were 21.9 (13.8; NC) and 13.9 (13.4; NC) months, respectively, in TCs and 13.8 (5.4; 16.6) and 11.0 (2.8; 16.9) months, respectively, in ACs. Patients’ quality of life did not deteriorate and LAN was well tolerated. Although recruitment stopped early and the predefined sample size was not met, SPINET is the largest prospective study to date of SSA therapy in SSTR-positive TCs and ACs and suggests clinical benefit in TCs.
Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK
Search for other papers by D Mandair in
Google Scholar
PubMed
Search for other papers by C Vesely in
Google Scholar
PubMed
Search for other papers by L Ensell in
Google Scholar
PubMed
Search for other papers by H Lowe in
Google Scholar
PubMed
Search for other papers by V Spanswick in
Google Scholar
PubMed
Search for other papers by J A Hartley in
Google Scholar
PubMed
Search for other papers by M E Caplin in
Google Scholar
PubMed
Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK
Search for other papers by T Meyer in
Google Scholar
PubMed
Search for other papers by Martyn E Caplin in
Google Scholar
PubMed
Search for other papers by Marianne Pavel in
Google Scholar
PubMed
Search for other papers by Jarosław B Ćwikła in
Google Scholar
PubMed
Search for other papers by Alexandria T Phan in
Google Scholar
PubMed
Search for other papers by Markus Raderer in
Google Scholar
PubMed
Search for other papers by Eva Sedláčková in
Google Scholar
PubMed
Search for other papers by Guillaume Cadiot in
Google Scholar
PubMed
Search for other papers by Edward M Wolin in
Google Scholar
PubMed
Search for other papers by Jaume Capdevila in
Google Scholar
PubMed
Search for other papers by Lucy Wall in
Google Scholar
PubMed
Search for other papers by Guido Rindi in
Google Scholar
PubMed
Search for other papers by Alison Langley in
Google Scholar
PubMed
Search for other papers by Séverine Martinez in
Google Scholar
PubMed
Search for other papers by Edda Gomez-Panzani in
Google Scholar
PubMed
Royal Free Hospital, Charité University Medicine Berlin, University of Warmia and Mazury, University of Texas MD Anderson Cancer Center, University Hospital, Department of Oncology of the First Faculty of Medicine and General Teaching Hospital, Robert‐Debré Hospital, Markey Cancer Center, Vall d'Hebron University Hospital, Western General Hospital, Università Cattolica del Sacro Cuore, Ipsen, Ipsen, Beaujon Hospital, Paris Diderot University, London, UK
Search for other papers by Philippe Ruszniewski in
Google Scholar
PubMed
Search for other papers by on behalf of the CLARINET Investigators in
Google Scholar
PubMed
In the CLARINET study, lanreotide Autogel (depot in USA) significantly prolonged progression-free survival (PFS) in patients with metastatic pancreatic/intestinal neuroendocrine tumours (NETs). We report long-term safety and additional efficacy data from the open-label extension (OLE). Patients with metastatic grade 1/2 (Ki-67 ≤10%) non-functioning NET and documented baseline tumour-progression status received lanreotide Autogel 120 mg (n=101) or placebo (n=103) for 96 weeks or until death/progressive disease (PD) in CLARINET study. Patients with stable disease (SD) at core study end (lanreotide/placebo) or PD (placebo only) continued or switched to lanreotide in the OLE. In total, 88 patients (previously: lanreotide, n=41; placebo, n=47) participated: 38% had pancreatic, 39% midgut and 23% other/unknown primary tumours. Patients continuing lanreotide reported fewer adverse events (AEs) (all and treatment-related) during OLE than core study. Placebo-to-lanreotide switch patients reported similar AE rates in OLE and core studies, except more diarrhoea was considered treatment-related in OLE (overall diarrhoea unchanged). Median lanreotide PFS (core study randomisation to PD in core/OLE; n=101) was 32.8 months (95% CI: 30.9, 68.0). A sensitivity analysis, addressing potential selection bias by assuming that patients with SD on lanreotide in the core study and not entering the OLE (n=13) had PD 24 weeks after last core assessment, found median PFS remaining consistent: 30.8 months (95% CI: 30.0, 31.3). Median time to further PD after placebo-to-lanreotide switch (n=32) was 14.0 months (10.1; not reached). This OLE study suggests long-term treatment with lanreotide Autogel 120 mg maintained favourable safety/tolerability. CLARINET OLE data also provide new evidence of lanreotide anti-tumour benefits in indolent and progressive pancreatic/intestinal NETs.
